Drug Patent Profile
Aripiprazole - Bristol-Myers Squibb/Otsuka Pharmaceutical
At a glance
- Drug Originator Otsuka Pharmaceutical
- Drug Licenced by Bristol-Myers Squibb; Lundbeck A/S
- Drug Class Antidepressants; Antipsychotics; Behavioural disorder therapies; Chlorobenzenes; Mood stabilisers; Piperazines; Quinolines; Small molecules
- Mechanism of Action Alpha 1 adrenergic receptor antagonists; Dopamine D2 receptor partial agonists; Dopamine D3 receptor antagonists; Dopamine D4 receptor antagonists; Histamine H1 receptor antagonists; Serotonin 1A receptor partial agonists; Serotonin 2C receptor partial agonists; Serotonin 5-HT2A receptor antagonists; Serotonin 7 receptor antagonists
- USA Patent Applicants OTSUKA
- USA Patents 41
- NDAs 5
- International Patents 399
- Patent Applications 4,953
Disclaimer
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.